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Summary The in vivo antiandrogenicity of Casodex has been confirmed and characterised. Androgen receptor
(AR) binding assays of rat ventral prostate gland cytosols revealed a relative binding affinity (RBA) for the
AR of 0.267 and a k, of 1.25 x 10-7M for Casodex. In addition, the peripheral selectivity of Casodex relative
to other non-steroidal antiandrogens was confirmed in that daily treatment of non-castrated rats with Casodex
(25 mg kg-1) did not elicit any changes in serum LH and testosterone concentrations relative to vehicle-treated
controls, whereas elevated serum LH and testosterone were observed in rats treated with flutamide
(25 mg kg-1). The peripheral selectivity of Casodex in the intact male rat was related to the distribution of
radiolabelled antiandrogen following intravenous injection. All tissues with the exception of the hypothalamus
and cerebral cortex (CC) sequestered radioactivity such that the tissue: serum ratio (TSR) for the drug was
greater than unity. In the testis, the TSR was less than unity 1 h after injection but approached unity 5 h after
injection and was greater than unity 10 h after injection. This may be explained by the presence of a
blood-testis barrier for the drug, resulting in delayed equilibration between the blood and testis tissue. By
comparison, an order of magnitude lower amounts of radioactivity in the hypothalamus and CC were
maintained for the 10 h period after injection. These data, together with known physicochemical properties of
Casodex suggest that a blood-brain barrier exists for the drug which results in exclusion of this antiandrogen
from central sites of androgen negative feedback and that this accounts for its peripherally selective anti-
hormonal profile.
The clinical use of antiandrogens (androgen receptor block-
ing drugs) is indicated in a variety of pathological states
(Mainwaring et al., 1987), but perhaps most importantly for
the treatment of androgen-dependent prostatic carcinoma
(Sagalowsky, 1985; Williams, 1985). In the earlier half of this
century, it was conclusively shown that castration achieved
either surgically or medically by the administration of oest-
rogens would provide temporary control of the progression
of this cancer (Huggins & Hodges, 1941; Huggins et al.,
1941). As a consequence, castration and/or oestrogens be-
came standard therapies for the treatment of prostatic cancer
(e.g. VACURG, 1967; Williams, 1985). Neither of these app-
roaches is, however, without problems. Oestrogen therapy
has long been associated with a higher cardiovascular mor-
bidity (VACURG, 1967; Bailar & Byar, 1970; Hedlund et al.,
1980; Henrikssen & Edhag, 1986), and elderly patients are
ill-equipped to deal with the surgical and psychological
trauma associated with castration.
The first antiandrogen used clinically, cyproterone acetate,
was seen to provide little improvement for prostate cancer
patients compared to standard therapy (Scott & Schrimer,
1966; Smith et al., 1973; Wein & Murphy, 1973; Jacobi et al.,
1980). Furthermore, the use of cyproterone acetate has been
associated with various adverse reactions (Markiewitz et al.,
1969; Wein & Murphy, 1973) which have, in part, been
attributed to the strong progestational activity of the drug
(Neumann & Steinbeck, 1974).
These findings led to the search for a non-steroidal antian-
drogen having a pure antiandrogenic profile, i.e. having no
other hormonal activity, in the hope that this would be
associated with a lower incidence of adverse reactions.
The use of the two non-steroidal pure antiandrogens so far
developed, flutamide (Neri et al., 1972) and nilutamide
(Raynaud et al., 1984), has, however, been associated with
elevated serum LH and testosterone concentrations resulting
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from interruption of androgen negative feedback on the
hypothalamic-pituitary-gonadal axis (Neumann & Steinbeck,
1974). Such actions of non-steroidal pure antiandrogens has
led to the controversial suggestion that their use to control
disease states in which hyperandrogenicity is aetiologically
implicated is inappropriate (Neumann & Steinbeck, 1974).
Recently, the structure and pharamacological properties of
a potent non-steroidal compound, Casodex (ICI 176,334),
having a pure antiandrogenic profile in rats and dogs but
which does not induce associated rises in serum LH and
testosterone concentrations, have been described (Furr et al.,
1987; Furr, 1988). Here, we confirm the in vitro receptor
binding properties of Casodex and its lack of stimulatory
effect on serum LH and testosterone. A possible explanation
is provided for the failure of this compound to induce in-
creased serum LH and testosterone concentrations in intact
male rodents, characteristic of other non-steroidal pure anti-
androgens.
Materials and methods
Animals
Specific pathogen-free albino male rats of the Wistar strain
were obtained from the Animal Breeding Unit, ICI Phar-
maceuticals (Alderley Park, Macclesfield, Cheshire, UK).
Chemicals
Cortisol, 5p-dihydrotestosterone, oestradiol-17P and progest-
erone were obtained from Steraloids Inc. (Croydon, Surrey,
UK). Triamcinolone acetonide was obtained from Sigma
Chemical Co. (Poole, Dorset, UK). Flutamide, Casodex and
3H-ICI 176,334 (specific activity 13.5 Ci mmol ') were provi-
ded by ICI Pharmaceuticals (Alderley Park, Macclesfield,
Cheshire, UK). 3H-mibolerone (specific activity 75-88
Ci mmol-') and 3H-testosterone (specific activity 60 Ci
mmol-') were obtained from Amersham International plc
(Amersham, Bucks., UK). Commonly used laboratory chem-
icals were obtained from recognised commercial sources and,
with the exception of certain organic solvents, were of
AnalaR grade or equivalent.
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Androgen receptor assay
Adult male Wistar rats were castrated by the scrotal route
under Fluothane (ICI plc) anaesthesia, 18-24 h before use.
Animals were killed by cervical dislocation, the ventral pros-
tate glands were removed, weighed and homogenised in app-
roximately 5 volumes TEDGM buffer (10 mM Tris:HCl
Ph 7.4; 1mM Na2EDTA; 10mM sodium molybdate; 20% (v/v)
glycerol; 1 mM dithiothreitol) and then centrifuged at
100,000g for 1 h at 0-4°C to yield the cytosol (soluble
fraction). Aliquots of cytosol were incubated with 3H-mibo-
lerone (3 x 10-9M) overnight at 0-4°C in the presence or
absence of various non-radioactive compounds. In addition,
all incubations contained a 1,000-fold molar excess of non-
radioactive triamcinolone acetonide to prevent binding of
3H-mibolerone to the progestin receptor (Murthy et al.,
1986). Bound and unbound radioactivity were separated by
charcoal adsorption. Specific binding was calculated by the
difference in the amount of tritium bound in the absence
(total binding) and presence (non-specific binding) of a 1,000-
fold molar excess of non-radioactive mibolerone. The
amount of tritium bound in the presence of competitors was
then, after correction for non-specific binding, expressed as a
percentage of specific binding seen in the absence of com-
petitors.
Radioimmunoassay ofserum LH and testosterone
Adult male Wistar rats (200-300 g) were randomly divided
into three groups of five animals, which were then dosed
orally daily with 0.5% polysorbate (0.25 ml per 100 g body
weight) either alone or containing suspensions of flutamide
(25 mg kg-') or Casodex (25 mg kg-'). Animals were bled
from the tail vein on day 0 before dosing, 4 h after the first
oral dose and then on days 7, 14, 21 and 28 of the study.
Serum was prepared from each blood sample. Serum LH was
assayed by a double antibody radioimmunoassay (RIA)
using well-characterised reagents: a rabbit anti-ovine LH
serum (GDN-15; Prof. G. Niswender, University of Colo-
rado, Fort Collins, Co, USA); purified ovine LH for iodina-
tion (LER-1056-C2; Prof. L.E. Riechert, Albany State
Medical College, New York, USA) and an ovine standard
NIH-LH-S21 (NIADDK, Bethesda, MD, USA). LH was
iodinated by the iodogen method and the sensitivity of the
assay was 0.5 ggl-' (Furr et al., 1987).
Serum testosterone was estimated by RIA using an anti-
serum (R45/3) raised in rabbits against testosterone-3-carb-
oxymethyl-oxime-bovine serum albumin. Significant cross-re-
actions were seen with 5a-dihyrotestosterone (57.1%, 19-nor-
testosterone (11.4%), and 5a-androstan-3p, 17p-diol (10.0%)
while oestradiol, progesterone and corticosterone showed
negligible cross-reactivity (<0.1%) (Furr et al., 1987). Serum
was extracted with 30 volumes of diethylether: petroleum
ether (50:50). After separation of the aqueous and solvent
phases by freezing in acetone/solid CO2 (Drikold, ICI Mond
Division, Runcorn, UK) the solvent phase was evaporated to
dryness by low heat under vacuum (Buchler Vortex Evapo-
rator). Antiserum at a dilution of 1/50,000 and 1,2-3H-testo-
sterone were added to the dried residue; the solutions were
mixed and incubated overnight at 4°C. A suspension of
dextran-coated charcoal was added to separate free and
bound hormone. The sensitivity of the assay was
0.87 nmol 1-1.
Distribution studies with 3H-ICI 176,334
Intact adult male Wistar rats (200-300 g) were injected into
the tail vein with 20gLCi (740 kBq) 3H-ICI 176,334 (equiva-
lent to 0.63 lag drug) in 0.2 ml isotonic saline. Rats were
killed at various times after injection, tissues were removed,
weighed and solubilised in NCS tissue solubiliser overnight at
50°C. Thep solutions were counted for tritium and tissue
radioactivity was expressed as d.p.m. mg-' tissue and then as
a tissue: serum ratio (TSR). Blood was collected from each
animal, serum prepared and counted for tritium without
solubilisation.
Statistical methods
Comparison of both mean TSR and mean serum LH or
testosterone concentrations between groups can be achieved
using analysis of variance (Anovar). Such comparison of
group means, however, requires homogeneity of variance
between groups, a phenomenon which can be tested by Bart-
lett's test (Armitage, 1971). This test demonstrated that this
precondition could not be met. In both cases, simple loga-
rithmic transformation of the data was sufficient to effect
homogeneity of variance. Accordingly, Anovar was per-
formed on the logarithmically transformed data (Armitage,
1971). It should be noted that although for clarity the text
refers to differences between group means, the statistical
significances presented refer strictly to differences between the
logarithmically transformed group means.
Results
Androgen receptor binding studies
Specific 3H-mibolerone binding to rat prostate cytosol was
readily depressed in a concentration-dependent fashion by
mibolerone but not by progesterone, cortisol, or 5P-dihyro-
testosterone (Figure 1). Some competition for androgen
receptor binding was seen by high concentration of oestra-
diol-17P (Figure 1).
In further experiments both Casodex and mibolerone
readily depressed specific 3H-mibolerone binding in a con-
centration-dependent fashion (Figure 2) with IC50 values of
1.2 x 10-6M and 3.2 x 10-9M respectively. The relative bind-
ing affinity (RBA) of Casodex is then given by the ratio of
the IC50 of Casodex to that of mibolerone. Thus, ascribing a
value of 100 to mibolerone the RBA of Casodex is 0.267.
Scatchard analysis (Scatchard, 1949) of 3H-mibolerone
binding to the rat prostate cytosol androgen receptor
revealed a dissociation constant, kd for the rat prostate
cytosol androgen receptor (mean of four experiments, data
not shown) of 0.35 x 10-9M for mibolerone. Thus, from
Bennett (1978), the k, (binding affinity constant or an app-
roximation of the dissociation constant) of Casodex for the
androgen receptor is estimated to be 1.25 x 10-7M.
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Figure 1 Semi-logarithmic plot of a dextran-coated charcoal
assay demonstrating the ability of 17p-oestradiol (A), proges-
terone (0), cortisol (A), 5p-dihyrotestosterone (0) and mibo-
lerone (0) to compete for specific 3H-mibolerone (3 x 10-9M)
binding to rat prostate cytosol androgen receptor. Points repre-
sent mean percentage of specific 3H-mibolerone binding seen in
the presence of competitors at various concentrations. S (100%)
is the mean specific binding of 3H-mibolerone in the absence of
competitors.666 S.N. FREEMAN et al.
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Figure 2 Semi-logarithmic plot of dextran-coated charcoal androgen receptor assays showing the ability of mibolerone (0) and
Casodex (0) to compete for specific 3H-mibolerone (3 x 10-9M) binding to rat prostate cytosol androgen receptor. Points represent
mean percentage of specific 3H-mibolerone binding at various competitor concentrations (So= 100%) (n =4). Vertical lines
represent the standard errors of the means. Competition curves allow the estimation of ICno values (concentration of competitor
required to inhibit specific binding by 50%) for Casodex and mibolerone against specific 3H-mibolerone binding as 1.2 x 10-6M
and 3.2 x 10-9M respectively.
Effects offlutamide and Casodex on serum LH and
testosterone concentrations in intact male rats
Before treatment of the animals there were no significant
differences (P>0.10) in either the mean serum LH or tes-
tosterone concentrations for the three groups (Figure 3).
Serum LH concentrations in the vehicle-treated control
group remained fairly constant throughout the 28 day dosing
period at 1-3ngml-l (Figure 3a). Treatment of animals
with flutamide resulted in a rapid increase in mean serum LH
from 1.26 ng ml-' before dosing to 5.32 ng ml-' 4 h after the
first oral dose (Figure 3a). This increase was maintained
throughout the course of the study and was found to be
significantly (P<0.05) greater than mean serum LH concen-
trations at all bleeding times in either the vehicle-treated
control group or the group treated with Casodex. In con-
trast, mean serum LH in animals dosed with Casodex did not
differ significantly from the vehicle-treated control group
over the 28-day period (Figure 3a).
The effects of the two antiandrogens on serum LH concen-
trations were paralleled by their effects on serum testo-
sterone. Flutamide caused a rapid and large increase in
serum testosterone from 3.73 ng ml-' before dosing to
10.77 ng ml-', 4 h after the first oral dose (Figure 4). Again,
this increase was maintained over the 28 day study and was
found to be significantly higher (P<0.05) than mean serum
testosterone concentrations at each of the intervals studied in
either the vehicle-treated control group or the group treated
with Casodex. The effect of Casodex on serum testosterone
concentrations was similar to that seen with serum LH. The
mean serum testosterone in animals treated with Casodex
was not essentially different from that in the vehicle-treated
control group (Figure 3b).
Distribution of3H-ICI 176,334 in intact male rats
The tissues studied can be divided into four major groups on
the basis of how they sequester radioactivity. First, the
organs of metabolism and excretion, the liver and kidney;
second, the androgen target tissues, prostate gland and
seminal vesicle, the non-target organs, spleen and lung, and
the anterior pituitary gland (APG); third, the hypothalamus
and other central nervous system (CNS) tissues; and fourth,
the testes.
The mean hepatic and renal TSRs 1, 5 or 10 h following
injection of 3H-ICI 176,334 were significantly higher
(P<0.05) than the corresponding means for the prostate
gland and spleen (Figure 4). The mean TSRs for the target
organs prostate gland and seminal vesicle were not signi-
ficantly different from the corresponding splenic mean at any
of the three times after injection (Figure 4). There was sub-
stantial uptake of 3H-ICI 176,334 by the anterior pituitary
gland (APG).
Mean testis TSR was seen to be significantly lower
(P<0.05) than the corresponding splenic means 1 h after
injection (Figure 4a). No such significant differences were
demonstrable either 5 h (Figure 4b) or 10 h (Figure 4c) after
injection of 3H-ICI 176,334.
The mean hypothalamic and cerebro-cortical TSRs I h, 5 h
and 10 h after injection were an order of magnitude lower
than the corresponding means for any of the other tissues
studied (Figure 4).
Discussion
We have used the synthetic radiolabelled androgen 3H-mibo-
lerone to characterise the interaction of Casodex with the rat
prostate cytosol androgen receptor. The competition curve
demonstrates that specific 3H-mibolerone binding is readily
depressed by androgen but not by progestin, glucocorticoid
or 5p-dihydrotestosterone. This in agreement with published
data (Schilling & Liao, 1984; Traish et al., 1986). The com-
petition for androgen binding seen with high concentrations
of oestradiol-17P has been previously reported (Fang et al.,
1969; Wilson & French, 1976; Brown et al., 1981; Schilling &
Liao, 1984; Traish et al., 1986). The parallel depression of
3H-mibolerone binding by non-radioactive mibolerone and
Casodex is strongly suggestive of competitive antagonism by
the antiandrogen. The estimate of the RBA of Casodex
against mibolerone biding is of the same order as that
previously reported for other non-steriodal antiandrogens
(Raynaud et al., 1979) and is reflected by the high k, of
Casodex for the androgen receptor of 1.25 x 10-7M.
The large and sustained increases in serum LH and tes-
tosterone concentrations seen following treatment of rats
with flutamide confirms earlier reports of similar effects of
this and other non-steroidal pure antiandrogens (Neri &
Monahan, 1972; Sodersten et al., 1975; Neri, 1977; Neumann
et al., 1977). The lack ofeffect of Casodex on serum concent-
rations of LH and testosterone is again in agreement with
earlier published work (Furr et al., 1987, Furr, 1988).
The distribution of 3H-ICI 176,334 was studied for a
period of 10 h after injection. This time course was chosen as
prolonged dosing of rats with Casodex is ineffective in raising
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Figure 4 Distribution of radioactivity in the intact male rat
following intravenous injection of 3H-ICI 176,334 as described in
the Materials and methods. Rats were killed I h (a) 5 h (b) or
10h (c) after injection and tissues were solubilised and counted
for tritium. Tissue radioactivity was expressed as d.p.m. mg-'
tissue weight and then as a tissue to serum ratio (TSR). Histo-
gram height reflects the mean TSR for each tissue in each group
(n = 4 or 5); the vertical lines represent the standard errors of the
means. Key: S, serum, APG, anterior pituitary gland; H, hypo-
thalamus; C, cerebral cortex; LG, lung; LV, liver; K, kidney; T,
testis; P, prostate gland; SV, seminal vesicles; SP, spleen.
10 20 30
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Figure 3 Radioimmunoassay of serum LH (a) and testosterone
(b) in intact male rats dosed orally daily with 0.5% polysorbate
(0.25 ml lOOg-' body weight) alone (0) or containing suspen-
sions of flutamide (25 mg kg-') (0) or Casodex (25 mg kg-')
(-). Animals were bled as described in Materials and methods
and serum was assayed for LH and testosterone. Points represent
the mean serum LH or testosterone (ngml-') for each of the
groups n = 5); vertical lines represent the standard errors of the
means. Logarithmically transformed group means were compared
by analysis of variance and statistical differences relative to the
vehicle-treated control group are denoted as: *P<0.05;
**P<0.01; ***P<0.001.
serum LH and testosterone concentrations (Furr et al., 1987)
and flutamide rapidly distributes to central feedback sites to
elevate the serum concentrations of these hormones. Both of
these observations suggest that delayed equilibration of
Casodex with central feedback areas is unlikely to be the
reason for the peripheral selectivity of this antiandrogen.
The distribution of tritium following injection of 'H-ICI-
176,334 reflects the distribution of the parent drug as there is
little, if any, biotransformation of this compound in the male
rat (L.R. Hughes, personal communication). The large
amounts of tritium in the liver and kidney presumably reflect
the long half-life of Casodex (Furr, 1988) and the rich blood
supply received by these organs. The distribution of tritium
to the testis is an order of magnitude lower than the spleen
1 h after injection and may reflect the presence of a blood:
testis barrier (Fawcett, 1973).
Knowledge of the distribution of radioactivity to the hypo-
thalamus and cerebral cortex is crucial in attempting to
understand the peripheral selectivity of Casodex. The order
of magnitude lower amounts of tritium present in these
tissues compared to all other tissues studied at all three times
after injection can most probably be explained by the
presence of a blood-brain barrier for the drug.
In general terms, free entry into the brain across the
blood-brain barrier occurs for substances having high lipid
solubility, a low degree of ionisation at physiological pH and
a lack of plasma protein binding (Brodie & Hogben, 1957;
Brodie et al., 1960; Schanker, 1965). Comparison of these
properties for both Casodex and flutamide may well provide
an explanation for their apparently divergent effects of serum
LH and testosterone concentrations. The log P (derived from
the oil : water partition coefficients) values for flutamide and
Casodex are 3.35 and 2.92 respectively (L.R. Hughes, per-
sonal communication). Although both antiandrogens are
highly lipid soluble, it is apparent that flutamide is signi-
ficantly more lipophilic than Casodex. Furthermore, Casodex
has been shown to be, on average, 95.4% plasma protein
bound in rats at concentrations ranging from 0.5 to
200 igml-' (H.J. Warwick & I.D. Cockshott, unpublished
observations). In addition, the recent finding that both fluta-
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mide and Casodex produce rises in LHRH secretion from
perfused hypothalami in vitro (Belchetz, 1987) shows that the
drug can exert antiandrogenic effects in the brain and would
appear to provide further indirect support for the concept of
barrier-mediated exclusion of Casodex from the central ner-
vous system.
These data suggest that the divergent effects of Casodex
and flutamide on serum LH and testosterone concentrations
can be explained by an inability of the former to penetrate
the blood-brain barrier. It is interesting that, in spite of
substantial uptake of3H-ICI 176,334 by the anterior pituitary
gland, there is no effect on LH secretion. This would imply
either that the drug does not behave as an antiandrogen at
this target tissue or that the pituitary gland is of little impor-
tance in the negative feedback effects of androgens in the rat.
It remains to be seen whether Casodex retains peripheral
selectivity in man but whatever the outcome this potent
antiandrogeii is likely to be of interest in the treatment of
androgen-responsive benign and malignant diseases.
S.N. Freeman was funded by a CASE Studentship from the Science
and Engineering Research Council and ICI Pharmaceuticals.
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